|
Symptom Severity
|
No.
|
Anti-Hsp70 No. (%)
|
Anti-Hsp60 No. (%)
|
|---|
| | |
1:10
|
1:20
|
1:40
|
1:80
|
1:10
|
1:20
|
1:40
|
1:80
|
|---|
|
Step1: intermittent
|
30
|
2 (6.7)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
|
Step2: mild persistent
|
36
|
10 (27.8)
|
5 (13.9)
|
2 (5.6)
|
1 (2.8)
|
3 (8.3)
|
1 (2.8)
|
1 (2.8)
|
1 (2.8)
|
|
Step3&4 moderate & severe persistent**
|
29
|
20 (69.0)
|
14 (48.3)
|
11 (37.9)
|
8 27.6)
|
14 (48.3)
|
5 (17.2)
|
4 (14.0)
|
4 (14.0)
|
|
R value*
| |
0.809
|
0.958
|
0.968
|
0.959
|
0.954
|
0.864
|
0.947
|
0.947
|
|
P value*
| |
0.000
|
0.000
|
0.000
|
0.001
|
0.000
|
0.000
|
0.016
|
0.016
|
- * The analyses of correlation of symptom severities with different dilutions of anti-Hsp70 and anti-Hsp60
- **: there are two severe persistent patients with asthma
